Jyong Biotech Ltd. (MENS)
- Previous close
30.01 - Open
30.20 - Bid 27.44 x 100
- Ask 37.70 x 100
- Day's range
26.40 - 30.71 - 52-week range
6.01 - 67.00 - Volume
28,926 - Avg. Volume
370,009 - Market cap (intra-day)
2.068B - Beta (5Y monthly) --
- PE ratio (TTM)
-- - EPS (TTM)
-0.04 - Earnings date --
- Forward dividend & yield --
- Ex-dividend date --
- 1y target est
--
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is headquartered in New Taipei City, Taiwan.
jyongbio.com--
Full-time employees
31 December
Fiscal year ends
Healthcare
Sector
Biotechnology
Industry
Recent news: MENS
View MorePerformance overview: MENS
Trailing total returns as of 28/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD return
1-year return
3-year return
5-year return
Statistics: MENS
View MoreValuation measures
Market cap
2.07B
Enterprise value
2.09B
Trailing P/E
--
Forward P/E
--
PEG ratio (5-yr expected)
--
Price/sales (ttm)
--
Price/book (mrq)
--
Enterprise value/revenue
--
Enterprise value/EBITDA
--
Financial highlights
Profitability and income statement
Profit margin
0.00%
Return on assets (ttm)
-17.59%
Return on equity (ttm)
--
Revenue (ttm)
--
Net income avi to common (ttm)
-3.02M
Diluted EPS (ttm)
-0.04
Balance sheet and cash flow
Total cash (mrq)
98k
Total debt/equity (mrq)
--
Levered free cash flow (ttm)
-1.73M
Compare To: MENS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.